NovaBridge Biosciences

Good morning and welcome to the Novabridge Biosciences first half 2026 corporate update and financial results call. At this time, all attendees are in a listen-only mode. A question and answer session will follow the formal presentation. As a reminder, this call is being recorded and a replay will be made available on the Novabridge website following the conclusion of the event. Some of the statements made on this call will include forward-looking statements within the meanings of the U.S. Private Securities and Litigation Reform Act of 1995. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business, including those set forth in the risk factor section of NOVA Bridge's annual report on Form 20F for the year ended December 31, 2025, and any other filings that are or may be made within the SEC. Please also carefully review the forward-looking statements disclaimer in the slide deck that accompanies this presentation. In addition, our statements are based on information available to us as of today, August 20th, 2026. Novabridge undertakes no obligation to revise or update any statements or information to reflect events or circumstances after the date of this conference call. I'd now like to turn the call over to Dr. Srishti Gupta, Chief Executive Officer of Novabridge Biosciences. Please go ahead, Srishti.

Thank you, Tara. Thank you everyone for joining us today. For those of you who have not yet had the pleasure to meet, I'm Srishti Gupta, Chief Executive Officer at Novabridge. It is really an honor to be here. I joined the company in July, so this is my first earnings call as CEO. Before discussing our first half results and our portfolio progress, I'd like to spend a few minutes sharing why I joined Novabridge and how I think about the opportunity ahead of us. Throughout my career, whether as a physician, a healthcare advisor, a board member, or most recently as a CEO of a global biopharmaceutical company, I have been motivated by a simple belief. Exceptional science only matters if it reaches patients. Too often though, promising medicines never reach their full potential. In many cases, the challenge is not the quality of the science itself. The challenge is advancing that science through development, regulatory review, financing, and ultimately commercialization. That is what attracted me to Novabridge. I believe the company has an opportunity to occupy a differentiated position in today's biotechnology landscape. Our goal is straightforward, to identify promising new medicines, advance them efficiently, and pursue the path that gives each program the best opportunity to succeed. We are working to bridge the gap between exceptional science and patient impact. Next slide, please. The opportunity to do this has never been greater. Today, more promising new medicines are being developed around the world than any point in our industry's history. We are especially seeing this in Asia, which has become an increasingly important source of new medicines and global licensing activity. But the point is not where the science originates. Where a medicine starts is becoming less important than how it is advanced. We believe that the capability is becoming increasingly important across our industry, and NovaBridge is well positioned at the intersection of innovation and translation. Next slide, please. NovaBridge has three key strengths. First, access. Through our relationships, networks, and experience, we believe we can identify promising opportunities, including therapies that others may overlook. Development expertise. We have the experience to advance programs through clinical development, generate meaningful proof of concept data, and make informed decisions about the best path forward. And third, capital allocation discipline. We do not believe that every potential new therapy should follow the same path. The right development, financing, or partnering strategy should be determined by the needs of the program. Structure should follow the asset and not the other way around. For us, this is not just a theoretical framework. Our two lead programs already demonstrate different aspects of this approach. GIVA Stomach reflects our ability to advance a promising program towards registrational development. BIS 101 reflects our ability to identify an attractive opportunity, acquire it, and build a focused organization around it. Next slide, please. Let me make this more concrete through our lead oncology program, GIVA Stomach. Beyond the promise of the medicine itself, I believe Givastomic demonstrates what disciplined execution can accomplish. Since the initial Phase 1b data presentation in July 2025, we have rapidly advanced the program towards a potential registrational path. Next slide, please. What stands out to me is the pace of progress over the past year. During the first half of 2026, we reported updated Phase 1b results initiated our global randomized phase two study and made important regulatory progress. Following our type B meeting with the FDA, we announced that Givastomig may be eligible for an accelerated approval pathway in first line HER2 negative, CLAUDIN 18.2 positive, PD-L1 positive gastroesophageal cancer. And in June, the FDA granted fast track designation for Givastomig in combination with nivolumab and chemotherapy. Taken together, these milestones have increased our confidence in the development pathway for the program. Looking ahead, we expect to present the updated Phase 1B dose expansion data at ESMO in October, and subject to ongoing planning and financing activities, continue to target initiation of a Phase 3 study as early as the fourth quarter of this year. Next slide, please. Let me now turn to why we're excited about GIVA Stomach. As we look at the competitive landscape, we believe GivaStomach has the potential to become an important first-line treatment option for patients with HER2- called an 18.2-positive gastric and gastroesophageal junction cancer. Three characteristics really stand out. First is the strong activity when added to standard immunochemotherapy. In the Phase 1b study, we observed encouraging response rates, disease control, and progression-free survival across the combination cohorts. Second, there's activity across a broad range of CLOD and 18.2 expression levels. Responses were observed across both higher and lower expression groups, which could support applicability across the broader patient population. And third, we believe practical adoption matters. Gevastomic is being developed as a conventional antibody therapy that can be integrated into existing treatment practice across a broad range of care settings. Taken together, we believe these attributes support the potential for Givastomic to become a differentiated first-line treatment option and reinforce our continued focus on advancing the program towards registrational development. Next slide, please. I would like to turn to our ophthalmology program. PHYS 101 is being advanced through Visara, NovaBridge's majority-owned ophthalmology subsidiary. We identified ophthalmology as an area with significant unmet need, particularly for therapies that can improve durability and reduce treatment burden. PHYS 101 became the foundation of that effort. We acquired what we believed was a differentiated asset and assembled an experienced ophthalmology leadership team, including the appointment of Dr. Jeff Nao as Chief Executive Officer of SARA to lead the next phase of development. Today, VIS 101 remains our lead ophthalmology program, and we continue to evaluate additional opportunities within the field over time. Next slide, please. We were initially attracted to VIS 101 because of a simple observation. In retinal vascular disease, outcomes have improved dramatically over the last decade, but treatment burden remains a significant challenge for patients and physicians. We believe durability remains one of the most important opportunities for innovation in ophthalmology. VIS 101 was purpose-designed to address that challenge. It is the only tetravalent VEGF-A and ANG2 peptibody with two binding sites for each target and a molecular design intended to provide both robust inhibition and extended durability. That differentiated profile is what initially attracted us to this therapy. Positive Phase 2a top-line results from earlier this year demonstrated improvements in visual acuity, reductions in retinal thickness, durable treatment responses, and a favorable safety profile. Based on those results, we're preparing to initiate a Phase 2b study in the second half of this year with the goal of further defining the optimal dose and advancing the program towards global Phase 3 development. Together, Jeeva Stomig and Biz101 illustrate two aspects of Dover Bridge's approach. One reflects our ability to advance a promising medicine through development. The other reflects our ability to identify attractive opportunities, acquire differentiated assets, and build focused organizations around them. These are the programs on which we're primarily focused today, and we believe both have important milestones ahead. With that, I'll turn the call over to Kyler to review our first half financial results.

Thank you, Srishti, and good morning, good evening, everyone. Nice to meet you, please. As of June 30, 2026, Novabridge had approximately $216 million in cash and investments, consisting of approximately $191 million in cash and cash equivalent and approximately $25 million in equity investment at fair value. Notably, this is a debt-free balance sheet continuing to be strong, which provides us with meaningful financial flexibility as we execute our strategic priorities. As you can see on this slide, our current financial resources are expected to support Novabrate through a number of important clinical and strategic inflection points across the portfolio. For Givastomic, this includes updated Phase 1b dose expansion data at ECMO 2026, completion of enrollment in the Phase 2 first-line gastroesophageal adenocarcinoma combination study, and the potential initiation of the Phase 3 registrational program as early as year-end 2026. Looking further ahead, our current runway extends through the anticipated Phase III interim data readout in 2028 for GVS-Dolny. Our financial position also supports continued development of Phase 101, including initiation and interim data readout of the Phase IIb Neurovascular AMD study and the planned Phase III initiation, as well as additional clinical milestones across the broader portfolio. As Srishti discussed, disabling capital allocation is a fundamental strength of the NovaBridge strategy, and we intend to deploy capital thoughtfully around programs and opportunities where we believe we can create meaningful value while maintaining the flexibility to pursue the financing, partnering, or corporate structure best suited to each asset. We believe our current balance sheet puts us in a strong position to execute that strategy while advancing the portfolio through multiple important value inflection points. With that, I'll turn the call back to Srishti for closing remarks. Srishti, back to you.